Skip to main
TWST
TWST logo

TWST Stock Forecast & Price Target

TWST Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 0%
Sell 11%
Strong Sell 0%

Bulls say

Twist Bioscience Corp has raised its gross margin guidance for FY25 to 49.5%, up from the previous estimate of 49%, and anticipates surpassing 50% gross margins by the end of Q4 FY25, indicating solid operational performance and profitability potential. The company has maintained its revenue guidance for FY25 while also increasing its adjusted EBITDA outlook, showcasing robust financial health and growth prospects. Furthermore, management believes that the upcoming spin-off will enhance visibility towards achieving adjusted EBITDA profitability, further strengthening the positive outlook for the company's financial future.

Bears say

Twist Bioscience Corp has reported that its data business has consistently posed a significant headwind to its adjusted EBITDA, with an impact of approximately $5 million per quarter. This ongoing drag on financial performance raises concerns about the profitability and operational efficiency of the company's overall business model. The recurring negative contributions from the data segment suggest persistent challenges that may hinder the company's financial growth and investor confidence moving forward.

TWST has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Twist Bioscience Corp (TWST) Forecast

Analysts have given TWST a Buy based on their latest research and market trends.

According to 9 analysts, TWST has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Twist Bioscience Corp (TWST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.